RWE Supports Repatha’s Effectiveness in Reducing Major Adverse Cardiovascular Events (MACE) in Patients with ASCVD. Data Presented at American Heart Association Scientific Sessi ...
Repatha® (evolocumab) can be used to help adults at increased risk for major adverse cardiovascular events lower their LDL-C ...
Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved statistically significant and clinically meaningful ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s ...
THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV ...
The clinical benefits and safety of Repatha have been studied for 15 years in 51 clinical trials with over 57,000 patients. 3,4 Repatha is approved in 74 countries, including the U.S., Japan, Canada ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback